Skip to main content
. Author manuscript; available in PMC: 2013 Dec 22.
Published in final edited form as: Mol Pharm. 2012 Jun 22;9(8):2280–2289. doi: 10.1021/mp300152v

Figure 3.

Figure 3

In vitro oncogene silencing. (a) Relative mRNA level after transfection of A549 cells with pooled siRNA in targeted LCP. (b) Comparison of each oncogene silencing efficiency for single siRNA formulated LCP versus pooled siRNA formulated LCP. (c) Western blot analysis of Hdm2 and c-myc after treatment of A549 cells with siRNA in different LCP formulations: 1) untreated; 2) control siRNA in targeted LCP; 3) pooled siRNA in non-targeted LCP; 4) pooled siRNA in targeted LCP. (d) ELISA analysis of VEGF in the A549 cell supernatant after treatment with pooled siRNA in different LCP formulations. Columns, mean (n = 3, in triplicate); bars, SD. *, p < 0.05.